Downregulation of AKAP12 may act as a candidate tumor biomarker of several malignancies, such as prostate cancer, breast cancer, gastric cancer and hepatocellular carcinoma [56, 57]. This evidence concerns the gene AKAP12 and prostate carcinoma.